Discovery of LL-K8-22 : A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex
Journal of Medicinal Chemistry · 13.04.2023 · 66 (7) · 4932-4951
DOI: 10.1021/acs.jmedchem.2c02045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 17.03.2023. Verfasst von Mingyu Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Hauptthemen laut MEDLINE: Cyclin C, Cyclin-Dependent Kinases. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Guangdong Science and Technology Department, Ministry of Science and Technology of the People's Republic of China, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
The CDK8-cyclin C complex is an important anti-tumor target, but unlike CDK8, cyclin C remains undruggable. Modulators regulating cyclin C activity directly are still under development. Here, a series of hydrophobic tagging-based degraders of the CDK8-cyclin C complex were designed, synthesized, and evaluated to identify the first dual degrader, LL-K8-22, which induced selective and synchronous degradation of CDK8 and cyclin C. Proteomic and immunoblot studies exhibited that LL-K8-22 significantly degraded CDK8 without reducing CDK19 and did not degrade other cyclin proteins except cyclin C. Moreover, LL-K8-22 showed enhanced anti-proliferative effects over its parental molecule, BI-1347, with potency increased by 5-fold in MDA-MB-468 cells. LL-K8-22 exhibited more pronounced effects on CDK8-cyclin C downstream signaling than BI-1347, suppressing STAT1 phosphorylation more persistently. RNA-sequencing analysis revealed that LL-K8-22 inhibited E2F- and MYC-driven carcinogenic transcriptional programs. Overall, LL-K8-22 is the first-in-class degrader of cyclin C and would be useful for studying the unknown functions of cyclin C.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.
- Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, Fuzhou 350117, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
- Center of Immunological Diseases, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Förderung
- Guangdong Science and Technology Department
- Ministry of Science and Technology of the People's Republic of China
- Natural Science Foundation of Fujian Province
- National Natural Science Foundation of China
- State Key Laboratory of Drug Research
- High-level new R&D institute
- National Administration of Traditional Chinese Medicine
- High-level Innovative Research Institute
Zitieren
APA
Wang, M., Lin, R., Li, J., Suo, Y., Gao, J., Liu, L., Zhou, L., Ni, Y., Yang, Z., Zheng, J., Lin, J., Zhou, H., Luo, C., & Lin, H. (2023). Discovery of LL-K8-22 : A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex. Journal of Medicinal Chemistry, 66(7), 4932-4951. https://doi.org/10.1021/acs.jmedchem.2c02045
Vancouver
Wang M, Lin R, Li J, Suo Y, Gao J, Liu L, et al. Discovery of LL-K8-22 : A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex. Journal of Medicinal Chemistry. 2023;66(7):4932-4951. doi:10.1021/acs.jmedchem.2c02045
BibTeX
@article{Wang2023,
author = {Wang, Mingyu and Lin, Rongkun and Li, Jiacheng and Suo, Yuying and Gao, Jing and Liu, Liping and Zhou, Liyuan and Ni, Yicheng and Yang, Ziqun and Zheng, Jie and Lin, Jin and Zhou, Hu and Luo, Cheng and Lin, Hua},
title = {Discovery of LL-K8-22 : A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {7},
pages = {4932--4951},
doi = {10.1021/acs.jmedchem.2c02045}
}
EUVIMED